GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF
EVerZom’s investigational drug candidate EViv, developed to treat ACLF, using its proprietary…
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting 2025
Preclinical studies demonstrated significant efficacy on systemic inflammation and organ function in…
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
November 08, 2025 17:13 ET Â | Source: Intellia Therapeutics, Inc. Deep, stable…
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.…
uniQure to Announce Third Quarter 2025 Financial Results
LEXINGTON, Mass. and AMSTERDAM, Nov. 06, 2025 (GLOBE NEWSWIRE) -- uniQure N.V.…
Baylor Genetics to Highlight Genetic Testing Use Cases and Advancements in Rare Disease at The National Society of Genetic Counselors 44th Annual Conference
HOUSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic…
LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase…
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 31, 2025 16:30 ET Â | Source: FibroBiologics, Inc. Advancing preparations to…
CeraVe Supports Global Skin Health Leaders to Deliver Care to Underserved Patients on World Skin Health Day
In Partnership with the International League of Dermatological Societies (ILDS) and the…
Anteris Technologies Announces First Patients Treated in DurAVR THV Global Pivotal Trial (the PARADIGM Trial)
MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) --…